Extending inferences from a randomized trial to a new target population.
Issa J DahabrehSarah E RobertsonJon Arni SteingrimssonElizabeth A StuartMiguel A HernánPublished in: Statistics in medicine (2020)
When treatment effect modifiers influence the decision to participate in a randomized trial, the average treatment effect in the population represented by the randomized individuals will differ from the effect in other populations. In this tutorial, we consider methods for extending causal inferences about time-fixed treatments from a trial to a new target population of nonparticipants, using data from a completed randomized trial and baseline covariate data from a sample from the target population. We examine methods based on modeling the expectation of the outcome, the probability of participation, or both (doubly robust). We compare the methods in a simulation study and show how they can be implemented in software. We apply the methods to a randomized trial nested within a cohort of trial-eligible patients to compare coronary artery surgery plus medical therapy versus medical therapy alone for patients with chronic coronary artery disease. We conclude by discussing issues that arise when using the methods in applied analyses.
Keyphrases
- coronary artery
- coronary artery disease
- phase iii
- healthcare
- phase ii
- end stage renal disease
- study protocol
- open label
- ejection fraction
- minimally invasive
- randomized controlled trial
- newly diagnosed
- electronic health record
- type diabetes
- double blind
- pulmonary artery
- peritoneal dialysis
- stem cells
- data analysis
- physical activity
- coronary artery bypass grafting
- deep learning
- patient reported outcomes
- placebo controlled
- coronary artery bypass
- aortic valve
- surgical site infection
- artificial intelligence